Do analysts prefer CUE or LXEO?

Lexeo Therapeutics has a consensus price target of $18.75, indicating a potential upside of 280.25%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lexeo Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lexeo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media prefer CUE or LXEO?

In the previous week, Cue Biopharma had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 8 mentions for Cue Biopharma and 6 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.44 beat Cue Biopharma's score of 0.19 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lexeo Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend XFOR or CUE?

X4 Pharmaceuticals currently has a consensus price target of $11.25, indicating a potential upside of 178.12%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe X4 Pharmaceuticals is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score X4 Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor XFOR or CUE?

In the previous week, Cue Biopharma had 6 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 8 mentions for Cue Biopharma and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.51 beat Cue Biopharma's score of 0.19 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cue Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RCKT or CUE?

Rocket Pharmaceuticals currently has a consensus target price of $8.57, indicating a potential upside of 144.55%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 3 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.30 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor RCKT or CUE?

In the previous week, Rocket Pharmaceuticals and Rocket Pharmaceuticals both had 8 articles in the media. Rocket Pharmaceuticals' average media sentiment score of 0.30 beat Cue Biopharma's score of 0.19 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cue Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend UPB or CUE?

Upstream Bio presently has a consensus price target of $29.67, suggesting a potential upside of 341.27%. Given Upstream Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Upstream Bio is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, UPB or CUE?

Cue Biopharma has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upstream Bio $2.85M 129.20 -$143.44M -$2.90 N/A Cue Biopharma $37.66M 4.49 -$26.60M -$27.02 N/A

Is UPB or CUE more profitable?

Cue Biopharma has a net margin of -435.83% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat Cue Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Upstream Bio -4,955.67% -48.40% -46.57% Cue Biopharma -435.83% -620.06% -291.15%

Does the media favor ARCT or CUE?

In the previous week, Cue Biopharma had 5 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 8 mentions for Cue Biopharma and 3 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.97 beat Cue Biopharma's score of 0.19 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cue Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Cue Biopharma (CUE) Competitors

$23.18 -0.80 (-3.34%)

Closing price 04:00 PM Eastern

Extended Trading

$23.69 +0.51 (+2.20%)

As of 04:15 PM Eastern

Compare

CUE vs. LXEO, XFOR, RCKT, UPB, and ARCT

Should you buy Cue Biopharma stock or one of its competitors? Cue Biopharma's main competitors and comparable companies include Lexeo Therapeutics (LXEO), X4 Pharmaceuticals (XFOR), Rocket Pharmaceuticals (RCKT), Upstream Bio (UPB), and Arcturus Therapeutics (ARCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cue Biopharma compare to Lexeo Therapeutics?

Cue Biopharma (NASDAQ:CUE) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, Cue Biopharma had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 8 mentions for Cue Biopharma and 6 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.44 beat Cue Biopharma's score of 0.19 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexeo Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cue Biopharma has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$37.66M	4.49	-$26.60M	-$27.02	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A

Lexeo Therapeutics has a consensus price target of $18.75, indicating a potential upside of 280.25%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lexeo Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Lexeo Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. Lexeo Therapeutics' return on equity of -41.85% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-435.83%	-620.06%	-291.15%
Lexeo Therapeutics	N/A	-41.85%	-38.03%

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cue Biopharma has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Summary

Lexeo Therapeutics beats Cue Biopharma on 10 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Cue Biopharma has a net margin of -435.83% compared to X4 Pharmaceuticals' net margin of -568.80%. X4 Pharmaceuticals' return on equity of -63.05% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
Cue Biopharma	-435.83%	-620.06%	-291.15%

Cue Biopharma has higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$15.85M	25.31	-$79.20M	-$1.20	N/A
Cue Biopharma	$37.66M	4.49	-$26.60M	-$27.02	N/A

X4 Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market.

In the previous week, Cue Biopharma had 6 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 8 mentions for Cue Biopharma and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.51 beat Cue Biopharma's score of 0.19 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cue Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

X4 Pharmaceuticals currently has a consensus price target of $11.25, indicating a potential upside of 178.12%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe X4 Pharmaceuticals is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 14.6% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

X4 Pharmaceuticals beats Cue Biopharma on 9 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to Rocket Pharmaceuticals?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

In the previous week, Rocket Pharmaceuticals and Rocket Pharmaceuticals both had 8 articles in the media. Rocket Pharmaceuticals' average media sentiment score of 0.30 beat Cue Biopharma's score of 0.19 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cue Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cue Biopharma has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
Cue Biopharma	$37.66M	4.49	-$26.60M	-$27.02	N/A

Rocket Pharmaceuticals currently has a consensus target price of $8.57, indicating a potential upside of 144.55%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Rocket Pharmaceuticals has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. Rocket Pharmaceuticals' return on equity of -52.77% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
Cue Biopharma	-435.83%	-620.06%	-291.15%

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Rocket Pharmaceuticals beats Cue Biopharma on 11 of the 15 factors compared between the two stocks.

How does Cue Biopharma compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

In the previous week, Cue Biopharma had 8 more articles in the media than Upstream Bio. MarketBeat recorded 8 mentions for Cue Biopharma and 0 mentions for Upstream Bio. Cue Biopharma's average media sentiment score of 0.19 beat Upstream Bio's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Upstream Bio	Neutral
Cue Biopharma	Neutral

Cue Biopharma has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	129.20	-$143.44M	-$2.90	N/A
Cue Biopharma	$37.66M	4.49	-$26.60M	-$27.02	N/A

Upstream Bio has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market.

35.0% of Cue Biopharma shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cue Biopharma has a net margin of -435.83% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Cue Biopharma	-435.83%	-620.06%	-291.15%

Upstream Bio presently has a consensus price target of $29.67, suggesting a potential upside of 341.27%. Given Upstream Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Upstream Bio is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Upstream Bio and Cue Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Cue Biopharma had 5 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 8 mentions for Cue Biopharma and 3 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.97 beat Cue Biopharma's score of 0.19 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cue Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcturus Therapeutics has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.47, suggesting that its share price is 147% more volatile than the broader market.

Arcturus Therapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 39.75%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cue Biopharma has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	4.96	-$65.78M	-$3.31	N/A
Cue Biopharma	$37.66M	4.49	-$26.60M	-$27.02	N/A

94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Arcturus Therapeutics has a net margin of -317.62% compared to Cue Biopharma's net margin of -435.83%. Arcturus Therapeutics' return on equity of -46.54% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Cue Biopharma	-435.83%	-620.06%	-291.15%

Summary

Arcturus Therapeutics beats Cue Biopharma on 13 of the 17 factors compared between the two stocks.

Get Cue Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CUE vs. The Competition

Export

Metric	Cue Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$169.71M	$3.99B	$7.29B	$12.73B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-0.86	11.76	271.37	24.13
Price / Sales	4.49	1,299.21	605.97	78.27
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	2.31	17.27	11.19	6.40
Net Income	-$26.60M	-$22.72M	$3.46B	$348.39M
7 Day Performance	-15.76%	2.96%	2.07%	1.09%
1 Month Performance	-27.51%	9.80%	7.40%	5.27%
1 Year Performance	-96.87%	54.94%	24.84%	16.29%

Cue Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CUE Cue Biopharma	0.5066 of 5 stars	$23.18 -3.3%	N/A	-96.8%	$168.38M	$37.66M	N/A	60	News Coverage Analyst Downgrade
LXEO Lexeo Therapeutics	2.319 of 5 stars	$4.95 -2.2%	$18.75 +278.8%	-0.4%	$406.13M	N/A	N/A	58
XFOR X4 Pharmaceuticals	1.6644 of 5 stars	$4.09 +1.5%	$11.25 +175.1%	+3.1%	$405.51M	$15.85M	N/A	80
RCKT Rocket Pharmaceuticals	2.5884 of 5 stars	$3.59 +3.2%	$8.57 +138.8%	-3.6%	$394.11M	N/A	N/A	240
UPB Upstream Bio	1.4935 of 5 stars	$6.93 +1.2%	$29.67 +328.1%	-60.5%	$379.56M	$2.85M	N/A	38

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CUE) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cue Biopharma (CUE) Competitors

CUE vs. LXEO, XFOR, RCKT, UPB, and ARCT

How does Cue Biopharma compare to Lexeo Therapeutics?

Summary

How does Cue Biopharma compare to X4 Pharmaceuticals?

Summary

How does Cue Biopharma compare to Rocket Pharmaceuticals?

Summary

How does Cue Biopharma compare to Upstream Bio?

Summary

How does Cue Biopharma compare to Arcturus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cue Biopharma (CUE) Competitors

CUE vs. LXEO, XFOR, RCKT, UPB, and ARCT

How does Cue Biopharma compare to Lexeo Therapeutics?

Does the media prefer CUE or LXEO?

Which has stronger valuation and earnings, CUE or LXEO?

Do analysts prefer CUE or LXEO?

Is CUE or LXEO more profitable?

Do institutionals & insiders believe in CUE or LXEO?

Which has more volatility & risk, CUE or LXEO?

Summary

How does Cue Biopharma compare to X4 Pharmaceuticals?

Is XFOR or CUE more profitable?

Which has preferable earnings & valuation, XFOR or CUE?

Which has more volatility & risk, XFOR or CUE?

Does the media favor XFOR or CUE?

Do analysts recommend XFOR or CUE?

Do insiders and institutionals believe in XFOR or CUE?

Summary

How does Cue Biopharma compare to Rocket Pharmaceuticals?

Does the media favor RCKT or CUE?

Which has stronger valuation & earnings, RCKT or CUE?

Do analysts recommend RCKT or CUE?

Which has more volatility and risk, RCKT or CUE?

Is RCKT or CUE more profitable?

Do institutionals & insiders believe in RCKT or CUE?

Summary

How does Cue Biopharma compare to Upstream Bio?

Does the media favor UPB or CUE?

Which has stronger earnings and valuation, UPB or CUE?

Which has more volatility and risk, UPB or CUE?

Do institutionals & insiders hold more shares of UPB or CUE?

Is UPB or CUE more profitable?

Do analysts recommend UPB or CUE?

Summary

How does Cue Biopharma compare to Arcturus Therapeutics?

Does the media favor ARCT or CUE?

Which has more risk and volatility, ARCT or CUE?

Do analysts prefer ARCT or CUE?

Which has stronger valuation & earnings, ARCT or CUE?

Do insiders & institutionals have more ownership in ARCT or CUE?

Is ARCT or CUE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools